Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
Chinje EC, Patterson AV, Saunders MP, Lockyer SD, Harris AL, Stratford IJ.
Chinje EC, et al. Among authors: patterson av.
Br J Cancer. 1999 Dec;81(7):1127-33. doi: 10.1038/sj.bjc.6690819.
Br J Cancer. 1999.
PMID: 10584872
Free PMC article.
The bioreductive drug tirapazamine (TPZ, SR 4233, WIN 59075) is a lead compound in a series of potent cytotoxins that selectively kill hypoxic rodent and human solid tumour cells in vitro and in vivo. ...Our results demonstrate that P450R plays a significant …
The bioreductive drug tirapazamine (TPZ, SR 4233, WIN 59075) is a lead compound in a series of potent cytotoxins that selectiv …